A diabetes drug could soon gain FDA approval for weight loss after manufacturer Eli Lilly said Thursday it showed patients lost significant amounts of weight after 72 weeks of treatment.
The trial evaluated 938 adults with obesity or overweight and type 2 diabetes, Lilly said in a news release.
The patients lost an average of 13.4% of their body weight on a 10-milligram dose and 15.7% on a 15-milligram dose compared to placebo. The company said it will present the full results of the study at an upcoming American Diabetes Association meeting and will be submitted to a peer-reviewed journal. Lilly said that based on the results, it will request regulatory approval from the FDA “in the coming weeks,” and expects the FDA to act by late this year.
Tirzepatide is a class of drugs known as GLP-1 receptor agonists. There other drugs like this already approved in the United States for weight loss, including semaglutide, a once-weekly injection, which is approved as Wegovy for patients with obesity and as Ozempic for treatment of type 2 diabetes. These drugs have been incredibly popular among celebrity influencers, and with use of the #Ozempic hashtag and others on social media, has led to unprecedented use of these drugs for weight loss, often among those who do not have obesity or type 2 diabetes. The popularity has left patients with type 2 diabetes and obesity struggling to find them because of shortages following this phenomenon.Eli Lilly and Company: “Lilly's tirzepatide achieved up to 15.
Singapore Latest News, Singapore Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Popular diabetes drug Mounjaro could be FDA-approved for weight loss this year, company saysA popular drug currently approved to treat Type 2 diabetes could soon also be approved for weight loss.
Read more »
Powerful new obesity drug poised to upend weight loss careA diabetes drug being tested for weight loss is poised to further upend obesity care
Read more »
Powerful new obesity drug poised to upend weight loss careAs a growing number of overweight Americans clamor for Ozempic and Wegovy — drugs touted by celebrities and on TikTok to pare pounds — an even more powerful obesity medicine is poised to upend treatment.
Read more »
Powerful new obesity drug poised to upend weight loss careA diabetes drug being tested for weight loss is poised to further upend obesity care. Drugmaker Eli Lilly and Co. reported Thursday that its drug tirzepatide helped people with diabetes who were overweight or had obesity lose up to 16% of their body weight over 17 months in a late-stage trial. For those without the disease, the drug has prompted losses of more than 20% of body weight. Known as Mounjaro for diabetes use, the drug has been used “off label” for weight loss since last year. Lilly is applying for fast-track approval from U.S. regulators and expects a decision this year. Analysts have predicted tirzepatide could become one of the top-selling drugs ever, with annual sales of more than $50 billion.
Read more »
Powerful new obesity drug poised to upend weight loss careAs a growing number of overweight Americans clamor for Ozempic and Wegovy — drugs touted by celebrities and on TikTok to pare pounds — an even more powerful obesity medicine is poised to upend treatment.
Read more »
Obesity drug poised to upend weight loss care; Disney sues DeSantis; Tucker Carlson emerges on Twitter🎧 Get the latest national, international, entertainment and sports news on our daily podcast.
Read more »